Core Viewpoint - Enhua Pharmaceutical reported continuous growth in its operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] Financial Performance - The company achieved an operating revenue of 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - The net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase year-on-year [1] R&D Investment - Enhua Pharmaceutical invested approximately 395 million yuan in research and development, representing a 23.97% increase compared to the previous year [2] - The company has over 70 ongoing research projects in the pipeline and holds the largest product line in the central nervous system drug sector in China [2] Innovative Drug Development - The company has 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - Collaborations include partnerships with San Sheng Pharmaceutical and Harvard Medical School for various drug development projects [3] Digital Healthcare Development - Enhua Pharmaceutical has established a digital healthcare platform since 2015, which includes online consultation and health services, with over 70,000 registered doctors and more than 2 million patient visits annually [4] - The company has developed several digital mental health products, including AI-based psychological risk screening systems and virtual reality tools [4] Expansion and Partnerships - The company operates 25 psychological clinics and has signed contracts with over 400 corporate clients, covering nearly 2 million individuals [5] - Enhua Pharmaceutical is actively pursuing overseas listing plans to expand financing channels and support business growth [5]